VORSCHAU

PRESSETERMINE
Presseclub Concordia
30.08.2023 00:00

AKTUELLES PRESSEFOTO



WETTER
Graz: bedeckt
24°
Innsbruck: Regen
22°
Linz: Regen
22°
Wien: bedeckt
20°
© wetter.net

Stadtname / PLZ

AKTIENKURSE
 
ADHOC
Mi, 11.01.2023 07:30
Meldung drucken Artikel weiterleiten
pta20230111009
Business news for the stock market
Pressefach Pressefach

4SC AG: European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T cell Lymphoma (CTCL)

Planegg-Martinsried (pta009/11.01.2023/07:30) - Planegg-Martinsried, Germany, 11 January 2023 – 4SC AG (4SC, FSE Prime Standard: VSC) today announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.

Dr. Jason Loveridge, CEO of 4SC AG commented; "This is another positive step in getting resminostat to market in the EU for patients with CTCL. The RESMAIN study is continuing as per our publicized projections, and as such we continue to expect to see top-line data available for this registration study in Q2 2023."

- Press release ends -

Further information

About 4SC

4SC AG ( http://www.4SC.com ) is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises one drug candidate in clinical development: resminostat ( http://www.4sc.com/product-pipeline/resminostat/ ).

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 20 employees as of 30 September 2022 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A3E5C40).

About resminostat

Resminostat ( http://www.4sc.com/product-pipeline/resminostat/ ) is an orally administered class I, IIb and IV histone deacetylase (HDAC) inhibitor that potentially offers an approach to treating different kinds of cancer. Resminostat demonstrated that it is well tolerated and can inhibit tumor growth and proliferation, cause tumor regression, and strengthen the body's immune response to cancer.  Resminostat is currently being investigated in a pivotal study in cutaneous T-cell lymphoma (CTCL) as maintenance treatment by 4SC in Europe and by Yakult Honsha in Japan. 

About cutaneous T-cell lymphoma (CTCL)

CTCL is a rare disease with approximately 5,000 patients being newly diagnosed in Europe each year. The disease arises from malignant transformation of T-cells, a specialized subgroup of immune cells, primarily affects the skin, but may ultimately involve lymph nodes, blood and visceral organs. 

Currently, CTCL is not curable and treatment options for advanced-stage CTCL are limited. Although patients respond to the available treatment options, the duration of response is often short-lived and declines as the severity of the disease increases. The key therapeutic challenge in advanced-stage CTCL is therefore to make remissions more durable by halting disease progression and improving patient's quality of life. 

About the RESMAIN study – resminostat for maintenance treatment of CTCL

The pivotal RESMAIN study ( https://clinicaltrials.gov/ct2/show/NCT02953301 ) is being conducted at more than 50 clinical centers in 11 European countries and Japan. It will include more than 200 patients who suffer from advanced-stage cutaneous T-cell lymphoma (CTCL) that have achieved disease control with systemic therapy. The patients are randomized 1:1 to receive either resminostat or placebo. Patients who experience disease progression – while being on placebo – will be offered resminostat in an open label treatment arm. 

The primary goal of the study is to determine whether maintenance treatment with resminostat prolongs progression-free survival and the key secondary objective is to prolong the time to symptom worsening (itching). A comprehensive biomarker program is also included in the study to ensure vital knowledge about the biological background of resminostat treatment in CTCL. 

About the concept of maintenance therapy

The pivotal RESMAIN study ( https://clinicaltrials.gov/ct2/show/NCT02953301 ) is focused on patients with advanced-stage, incurable cutaneous T-cell lymphoma (CTCL). Such patients suffer from painful and itchy skin lesions resulting in disfigurement and a severely impaired quality of life. Furthermore, lymph nodes, blood or visceral organs can be involved. The current therapeutic options rarely provide long-lasting responses or stabilization of disease for meaningful periods, with most patients progressing within several months. 

Resminostat is being evaluated as maintenance treatment - a unique innovative treatment approach in CTCL (Stadler et al., 2021) - intended to prolong the period patients are stable and not progressing. Furthermore, recent preclinical data suggests that resminostat has the potential to alleviate the itching in CTCL patients, thereby additionally improving their quality of life. 

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact

ir-pr@4sc.com
+49 89 700763-0

(Ende)

Aussender: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Deutschland
Ansprechpartner: Jason Loveridge
Tel.: +49 89 700763-0
E-Mail:
Website: www.4sc.de
ISIN(s): DE000A3E5C40 (share)
Börsen: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
4SC AG
   
Wie fanden Sie diese Meldung?
Weitersagen
likes dislike Share Share |
Social Media
ETARGET

FOCUSTHEMA


SPECIALS


Werbung
middleAdvertising